TY - JOUR
T1 - NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980-2017
T2 - a nationwide cohort study
AU - Eriksen, Patrick R. G.
AU - Clasen-Linde, Erik
AU - Brown, Peter de Nully
AU - Haunstrup, Laura
AU - Christoffersen, Mette
AU - Asdahl, Peter
AU - Thomsen, Troels Moller
AU - von Buchwald, Christian
AU - Heegaard, Steffen
PY - 2022
Y1 - 2022
N2 - Compared to Asian and Latin American populations, sinonasal NK- or T-cell lymphoma is rare in Europe. All patients with sinonasal NK- or T-cell lymphoma in Denmark from 1980 to 2017 were validated histologically, and the disease behavior and demographics were extracted from medical records and national registries. Prognostic factors associated with mortality were determined using survival statistics. We included 56 patients: 40 extranodal NK/T-cell lymphoma (nasal type) (ENKTCL) and 16 peripheral T-cell lymphoma (not otherwise specified) (PTCL). The median age was 66, and most patients were male (72%). The ENKTCL and PTCL 5-year overall survival was 48% and 50%, respectively; progression-free survival was 38% for both. With ENKTCL, stage and performance status increased mortality significantly (HR = 8.6; p < 0.001 and HR = 4.23; p = 0.04). In conclusion, disseminated disease had a dismal outcome and the onset of ENKTCL in this ethnically homogeneous European cohort was about a decade later than reported in Asian populations.
AB - Compared to Asian and Latin American populations, sinonasal NK- or T-cell lymphoma is rare in Europe. All patients with sinonasal NK- or T-cell lymphoma in Denmark from 1980 to 2017 were validated histologically, and the disease behavior and demographics were extracted from medical records and national registries. Prognostic factors associated with mortality were determined using survival statistics. We included 56 patients: 40 extranodal NK/T-cell lymphoma (nasal type) (ENKTCL) and 16 peripheral T-cell lymphoma (not otherwise specified) (PTCL). The median age was 66, and most patients were male (72%). The ENKTCL and PTCL 5-year overall survival was 48% and 50%, respectively; progression-free survival was 38% for both. With ENKTCL, stage and performance status increased mortality significantly (HR = 8.6; p < 0.001 and HR = 4.23; p = 0.04). In conclusion, disseminated disease had a dismal outcome and the onset of ENKTCL in this ethnically homogeneous European cohort was about a decade later than reported in Asian populations.
KW - Extranodal lymphoma
KW - paranasal neoplasms
KW - nasal neoplasms
KW - prognosis
KW - demography
KW - natural killer cell
KW - T-cell
KW - CLINICAL DIFFERENCES
U2 - 10.1080/10428194.2022.2087069
DO - 10.1080/10428194.2022.2087069
M3 - Journal article
C2 - 35699970
VL - 63
SP - 2579
EP - 2588
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 11
ER -